Nanomedicine in Action: An Overview of Cancer Nanomedicine on the Market and in Clinical Trials

Table 1

Nanomedicines approved by one or more regulatory bodies.

Product	Nanoplatform/agent	Indication	Status	Company
Doxil	PEGylated liposome/doxorubicin hydrochloride	Ovarian cancer	Approved 11/17/1995; FDA50718	Ortho Biotech; (acquired by JNJ)
Myocet	Non-PEGylated liposomal doxorubicin nanomedicine	Metastatic breast cancer	Approved in Europe and Canada, in combination with cyclophosphamide	Sopherion Therapeutics, LLC in North America and Cephalon, Inc. in Europe
DaunoXome	Lipid encapsulation of daunorubicin	First-line treatment for patients with advanced HIV-associated Kaposi's sarcoma	Approved in the USA	Galen Ltd.
ThermoDox	Heat-activated liposomal encapsulation of doxorubicin	Breast cancer, primary liver cancer	Received Fast Track Designation, approval expected by 2013	Celsion
Abraxane	Nanoparticulate albumin/paclitaxel	Various cancers	Approved 1/7/2005; FDA21660	Celgene
Rexin-G	Targeting protein tagged phospholipid/microRNA-122	Sarcoma, osteosarcoma, pancreatic cancer, and other solid tumor	Fully approved in Philippine; Phase II/III (Fast Track Designation, Orphan Drug Status Acquired) in USA	Epeius Biotechnologies Corp.
Oncaspar	PEGylated asparaginase	Acute lymphoblastic leukemia	Approved 24/06/2006	Enzon Pharmaceuticals, Inc.
Resovist	Iron oxide nanoparticles coated with carboxydextran	Liver/spleen lesion imaging	In 2001, approved for the European market	Bayer Schering Pharma AG
Feridex	Iron oxide nanoparticles coated with dextran	Liver/spleen lesion imaging	Approved by US-FDA in 1996	Berlex Laboratories
Endorem	Iron oxide nanoparticles coated with dextran	Liver/spleen lesion imaging	Approved in Europe	Guerbet